Sunny Pharmtech Inc. (6676.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$9.93 (-0.40%) as of
Key statistics
- Market cap
- 1.68B
- EPS (TTM)
- -2.14
- Dividend yield
- 0.00%
- 52-week range
- 9.53 – 19.10
- Beta
- 0.30
- Revenue (TTM)
- 233.36M
- Profit margin
- -139.33%
- Volume
- 193.34k
About Sunny Pharmtech Inc.
Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug formulations and raw materials in Taiwan, the United States, and internationally. It offers lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; and aminocaproic acid tablets for blood diseases and hyper-proteolytic enzymes. It also provides carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage, as well as Cyclophosphamide injection for malignant diseases. The company was founded in 2014 and is based in Taoyuan City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taoyuan City, Taiwan
- Employees
- 160
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.